METHODS: This prospective quasi experimental study involved 56 patients, divided into a study group receiving preemptive etoricoxib 120 mg before surgery and postoperative etoricoxib 120 mg (n = 28), and a control group receiving preemptive placebo before surgery and postoperative etoricoxib 120 mg (n = 28). Follow-up assessments were conducted at 3- and 7-days post-surgery, recording swelling, trismus, and adverse events. Patients rated perceived pain using the visual analog scale (VAS) and completed an oral health-related quality of life (OHRQoL) questionnaire at specified intervals. Statistical analysis employed non-parametric tests (i.e., the Mann-Whitney test, Friedman test, and Wilcoxon sign test) with P < 0.05.
RESULTS: Significantly lower VAS scores were reported in the study group throughout the follow-up period (P < 0.05). Pharmacological protocol did not have a significant impact on postoperative edema and trismus (P > 0.05). However, double etoricoxib intake significantly improved postoperative quality of life on day 3 after surgery (P < 0.05).
CONCLUSIONS: Pre- and postoperative etoricoxib 120 mg intake in third molar surgery reduced postoperative pain and enhanced postoperative quality of life on day 3 after surgery. Importantly, it was equally effective in managing swelling and trismus compared to exclusive postoperative intake.
CONCLUSIONS: Preemptive etoricoxib use may decrease patient discomfort following impacted mandibular third molar extraction.
方法:这项前瞻性准实验研究涉及56名患者,分为研究组,接受术前先发制人的依托考昔120mg和术后依托考昔120mg(n=28),对照组在手术前接受先发制人安慰剂,术后接受依托考昔120mg(n=28)。术后3天和7天进行随访评估,记录肿胀,刺耳,和不良事件。患者使用视觉模拟量表(VAS)对感知的疼痛进行评分,并以指定的时间间隔完成口腔健康相关生活质量(OHRQoL)问卷。统计分析采用非参数检验(即,Mann-Whitney测试,弗里德曼测试,和Wilcoxon符号检验),P<0.05。
结果:在整个随访期间,研究组的VAS评分显著降低(P<0.05)。药物治疗方案对术后水肿和张口无明显影响(P>0.05)。然而,术后第3天服用双依托考昔可显著改善患者术后生活质量(P<0.05)。
结论:第三磨牙手术前后摄入依托考昔120mg可减轻术后疼痛,提高术后第3天的生活质量。重要的是,与术后独家摄入相比,它在控制肿胀和三联管上同样有效.
结论:抢先使用依托考昔可以减少下颌阻生第三磨牙拔除后患者的不适。